StockData
Mesoblast Ltd logo

Mesoblast Ltd (MESO) stock

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30
$11.18−0.46 (-3.95%)

Close on Nov 19, 2026Market cap $1.45BP/E –Yield –

Mesoblast gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2026 it was $103.58M, up 758.3% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2026Jun 30, 2026$103.58M+758.3%
FY2025Jun 30, 2025$12.07M+104.5%
FY2024Jun 30, 2024$5.90M-21.3%
FY2023Jun 30, 2023$7.50M–

More Mesoblast figures

See a number that looks wrong?